Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Rating)’s stock price fell 7.2% during trading on Wednesday . The stock traded as low as $1.78 and last traded at $1.84. 49,878 shares were traded during mid-day trading, a decline of 29% from the average session volume of 70,441 shares. The stock had previously closed at $1.98.
Wall Street Analyst Weigh In
Separately, EF Hutton Acquisition Co. I assumed coverage on shares of Coeptis Therapeutics in a report on Monday, December 12th. They issued a “buy” rating and a $6.00 price target on the stock.
Coeptis Therapeutics Stock Performance
The firm has a 50 day moving average price of $1.98. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 0.02.
Coeptis Therapeutics Company Profile
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies.
- Get a free copy of the StockNews.com research report on Coeptis Therapeutics (COEP)
- Can Amazon Lead Consumer Stocks To A Big Rally In 2023?
- Keep These 3 Dividend Contenders on the 2023 Watch List
- GE HealthCare Technologies Soars As GE Legacy Business Plummets
- 3 Energy Stock Winners With More in the Tank
- 3 Health Care Stocks Paying Reliable Dividends
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.